REG1V logo

Revenio Group Oyj Stock Price

HLSE:REG1V Community·€630.5m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 13 Fair Values set on narratives written by author

REG1V Share Price Performance

€23.70
-9.08 (-27.70%)
18.8% undervalued intrinsic discount
€29.20
Fair Value
€23.70
-9.08 (-27.70%)
21.7% undervalued intrinsic discount
€30.27
Fair Value
Price €23.70
AnalystConsensusTarget €30.27

REG1V Community Narratives

AnalystConsensusTarget·
Fair Value €29.2 19.0% undervalued intrinsic discount

Global Ophthalmic Diagnostics Will Expand Through AI Integration

0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative

Recent REG1V News & Updates

Revenio Group Oyj's (HEL:REG1V) 25% Jump Shows Its Popularity With Investors

May 14
Revenio Group Oyj's (HEL:REG1V) 25% Jump Shows Its Popularity With Investors

Earnings Miss: Revenio Group Oyj Missed EPS By 5.8% And Analysts Are Revising Their Forecasts

May 02
Earnings Miss: Revenio Group Oyj Missed EPS By 5.8% And Analysts Are Revising Their Forecasts

Is Revenio Group Oyj (HEL:REG1V) A Risky Investment?

Apr 23
Is Revenio Group Oyj (HEL:REG1V) A Risky Investment?

Here's What Analysts Are Forecasting For Revenio Group Oyj (HEL:REG1V) After Its Annual Results

Feb 16
Here's What Analysts Are Forecasting For Revenio Group Oyj (HEL:REG1V) After Its Annual Results

Revenio Group Oyj Key Details

€107.2m

Revenue

€30.7m

Cost of Revenue

€76.5m

Gross Profit

€58.4m

Other Expenses

€18.1m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 30, 2025
Earnings per share (EPS)
0.68
Gross Margin
71.39%
Net Profit Margin
16.88%
Debt/Equity Ratio
8.8%

Revenio Group Oyj Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

0 Risks
3 Rewards

About REG1V

Founded
2001
Employees
251
CEO
Jouni Toijala
WebsiteView website
www.reveniogroup.fi

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used for measuring IOP on animal patients by general veterinary practitioners, veterinary ophthalmologists and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Finnish Market Performance

  • 7 Days: 0.1%
  • 3 Months: 3.5%
  • 1 Year: 8.7%
  • Year to Date: 14.5%
The Information Technology sector gained 5.2% while the market remained flat over the last week. As for the longer term, the market has risen 9.2% in the past 12 months. Looking forward, earnings are forecast to grow by 16% annually. Market details ›